Evidence map›Paper›PMID 42282776›Full record

ArticlebioRxiv : the preprint server for biology2026

Engineering Biosensors to Enhance Monoterpene Indole Alkaloid Production in Yeast.

Maxence Holtz, Simon D'Oelsnitz, Cecília Castellví Domingo, Niklas G Madsen, Mars Yu Hong, Jonathan Asmund Arnesen, Aafke C A van Aalst, Samantha de Haan, Christopher K Weingarten, Ditte H Welner and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Maxence HoltzThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0009-0003-6976-8034
Simon D'OelsnitzSynthetic Biology HIVE, Harvard Medical School, Boston, USA.ORCID 0000-0001-7512-9157
Cecília Castellví DomingoThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.
Niklas G MadsenThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0009-0001-4599-4040
Mars Yu HongThe University of Texas at Austin, Austin, USA.
Jonathan Asmund ArnesenThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0003-0053-2122
Aafke C A van AalstThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0009-0008-7417-7438
Samantha de HaanThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.
Christopher K WeingartenThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0009-0004-1246-0415
Ditte H WelnerThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0001-9297-4133
Pamela A SilverSynthetic Biology HIVE, Harvard Medical School, Boston, USA.ORCID 0000-0002-7856-4071
Y Jessie ZhangThe University of Texas at Austin, Austin, USA.ORCID 0000-0002-9360-5388
Michael K JensenBiomia ApS, Copenhagen, Denmark.ORCID 0000-0001-7574-4707
Carlos G Acevedo-RochaThe Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0002-5877-2084

Funding

Deciphering the phosphorylation pattern of RNA polymerase II for eukaryotic transcriptionR35GM148356 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Yan Jessie Zhang · 2023 to 2026
$2.3M
NIGMS NIH HHS R35 GM148356
6 · The paper itself

Abstract

Monoterpene Indole Alkaloids (MIAs) are a diverse family of plant natural products with various medicinal applications. Although MIAs, such as vinblastine and reserpine, are clinically validated, sourcing of MIAs for clinical use or drug discovery from natural resources or via chemical synthesis is hampered due to their scarcity and chemical complexity. Refactoring MIA biosynthesis pathways in microbial cell factories could offer an alternative, more stable and potentially sustainable manufacturing route for alkaloid medicines and novel therapies. However, reaching commercially attractive titers, rates and yields remains challenging owing to the length and complexity of these metabolic pathways. One critical bottleneck is the low screening throughput and very high cost of the analytical methods used to quantify MIA for optimizing production. In this study, we evolved RamR, a promiscuous bacterial transcription factor to respond to five different MIAs, resulting in highly sensitive and selective sensor variants (EC

Indexed as

alkaloid biomanufacturingBiosensordirected evolutionmetabolic engineeringmonoterpene indole alkaloidsplant natural productsRamRstrictosidinesynthetic biologyyeast cell factory

Identifiers

PMID42282776
PMCPMC13251997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.